Chromocell Therapeutics announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders: “With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering share our mission, outline the current status of our development programs, and discuss our growth and operational plans. We successfully closed our IPO on February 21 raising gross proceeds of approximately $6.6M. Notably, almost all shares of common stock held by 5% holders, directors and officers of the Company prior to the IPO are subject to formal lock-up agreements….We expect that the net proceeds from our IPO will allow us to focus on accelerating the development of a portfolio of non-opioid pain treatments and related therapies. Opioids effectively treat pain, but their use often leads to serious side effects, including addiction and mortality. Despite the explosive growth of opioid addiction and the ongoing suffering of many patients, there has been a lack of new pain treatment therapies. We intend to build a robust pipeline of products to address several pain indications with molecules that show no addictive or euphoric properties.” *
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRO:
- Chromocell Issues Letter to Stockholders from Chief Executive Officer
- Chromocell Announces New Eye Pain Treatment Initiative
- Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
- Chromocell Therapeutics launches eye pain treatment program
- Chromocell Therapeutics Appoints Experienced CEO Francis Knuettel II
Questions or Comments about the article? Write to editor@tipranks.com